
Paolo Bironzo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3728804/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Deep learning using tumor HLA peptide mass spectrometry datasets improves neoantigen identification. Nature Biotechnology, 2019, 37, 55-63.	17.5	203
2	Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis. Lancet Respiratory Medicine,the, 2018, 6, 771-781.	10.7	167
3	Targeted Next-Generation Sequencing of Cancer Genes in Advanced Stage Malignant Pleural Mesothelioma: A Retrospective Study. Journal of Thoracic Oncology, 2015, 10, 492-499.	1.1	142
4	Understanding and overcoming the mechanisms of primary and acquired resistance to abiraterone and enzalutamide in castration resistant prostate cancer. Cancer Treatment Reviews, 2015, 41, 884-892.	7.7	141
5	Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy. , 2021, 9, e002421.		80
6	A review of guidelines for lung cancer. Journal of Thoracic Disease, 2018, 10, S1556-S1563.	1.4	64
7	Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50%. Cancer Immunology, Immunotherapy, 2020, 69, 2209-2221.	4.2	60
8	Pathogenesis, Clinical Manifestations and Management of Immune Checkpoint Inhibitors Toxicity. Tumori, 2017, 103, 405-421.	1.1	52
9	Sensitivity to asbestos is increased in patients with mesothelioma and pathogenic germline variants in <i>BAP1</i> or other DNA repair genes. Genes Chromosomes and Cancer, 2018, 57, 573-583.	2.8	43
10	Bromodomain inhibition exerts its therapeutic potential in malignant pleural mesothelioma by promoting immunogenic cell death and changing the tumor immune-environment. Oncolmmunology, 2018, 7, e1398874.	4.6	41
11	Potential Diagnostic and Prognostic Role of Microenvironment in Malignant Pleural Mesothelioma. Journal of Thoracic Oncology, 2019, 14, 1458-1471.	1.1	41
12	Strategies for managing ACTH dependent mineralocorticoid excess induced by abiraterone. Cancer Treatment Reviews, 2013, 39, 966-973.	7.7	37
13	Antagonists of growth hormone-releasing hormone (GHRH) inhibit the growth of human malignant pleural mesothelioma. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 2226-2231.	7.1	29
14	Wnt/ILâ€1β/ILâ€8 autocrine circuitries control chemoresistance in mesothelioma initiating cells by inducing ABCB5. International Journal of Cancer, 2020, 146, 192-207.	5.1	29
15	DNA repair gene expression level in peripheral blood and tumour tissue from non-small cell lung cancer and head and neck squamous cell cancer patients. DNA Repair, 2012, 11, 374-380.	2.8	28
16	Quality of life analysis in lung cancer: A systematic review of phase III trials published between 2012 and 2018. Lung Cancer, 2020, 139, 47-54.	2.0	28
17	New emerging targets in cancer immunotherapy: the role of VISTA. ESMO Open, 2019, 4, e000683.	4.5	24
18	Predicting immunotherapy outcomes under therapy in patients with advanced NSCLC using dNLR and its early dynamics. Furopean Journal of Cancer, 2021, 151, 211-220.	2.8	24

Paolo Bironzo

#	Article	IF	CITATIONS
19	Thymidylate synthase drives the phenotypes of epithelial-to-mesenchymal transition in non-small cell lung cancer. British Journal of Cancer, 2021, 124, 281-289.	6.4	22
20	A Prospective Phase II Single-arm Study of Niraparib Plus Dostarlimab in Patients With Advanced Non–small-cell Lung Cancer and/or Malignant Pleural Mesothelioma, Positive for PD-L1 Expression and Germline or Somatic Mutations in the DNA Repair Genes: Rationale and Study Design. Clinical Lung Cancer, 2021, 22, e63-e66.	2.6	22
21	Major breakthroughs in lung cancer adjuvant treatment: Looking beyond the horizon. Cancer Treatment Reviews, 2021, 101, 102308.	7.7	21
22	Exploring the role of respiratory microbiome in lung cancer: A systematic review. Critical Reviews in Oncology/Hematology, 2021, 164, 103404.	4.4	18
23	Pathological Characterization of Tumor Immune Microenvironment (TIME) in Malignant Pleural Mesothelioma. Cancers, 2021, 13, 2564.	3.7	16
24	Efficacy of neurokinin-1 receptor antagonists in the prevention of chemotherapy-induced nausea and vomiting in patients receiving carboplatin-based chemotherapy: A systematic review and meta-analysis. Critical Reviews in Oncology/Hematology, 2018, 124, 21-28.	4.4	15
25	Antiandrogen withdrawal syndrome (AAWS) in the treatment of patients with prostate cancer. Endocrine-Related Cancer, 2018, 25, R1-R9.	3.1	13
26	Resistance to anaplastic lymphoma kinase inhibitors: knowing the enemy is half the battle won. Translational Lung Cancer Research, 2020, 9, 2545-2556.	2.8	13
27	A systematic review and meta-analysis of trials assessing PD-1/PD-L1 immune checkpoint inhibitors activity in pre-treated advanced stage malignant mesothelioma. Critical Reviews in Oncology/Hematology, 2022, 172, 103639.	4.4	13
28	Surrogate Endpoints in Second-Line Trials of Targeted Agents in Metastatic Colorectal Cancer: A Literature-Based Systematic Review and Meta-Analysis. Cancer Research and Treatment, 2017, 49, 834-845.	3.0	12
29	Single agent VS-6766 or VS-6766 plus defactinib in <i>KRAS</i> -mutant non-small-cell lung cancer: the RAMP-202 phase II trial. Future Oncology, 2022, 18, 1907-1915.	2.4	11
30	Pulmonary Arterial Hypertension in ALK Receptor Tyrosine Kinase–Positive Lung Cancer Patient: Adverse Event or Disease Spread?. Journal of Thoracic Oncology, 2019, 14, e38-e40.	1.1	10
31	Systematic Review of adverse events reporting in clinical trials leading to approval of targeted therapy and immunotherapy. Future Oncology, 2019, 15, 2543-2553.	2.4	10
32	Targeting KRAS in NSCLC: Old Failures and New Options for "Non-G12c―Patients. Cancers, 2021, 13, 6332.	3.7	10
33	Emergency room comprehensive assessment of demographic, radiological, laboratory and clinical data of patients with COVID-19: determination of its prognostic value for in-hospital mortality. Internal and Emergency Medicine, 2022, 17, 205-214.	2.0	9
34	Moving from histological subtyping to molecular characterization: new treatment opportunities in advanced non-small-cell lung cancer. Expert Review of Anticancer Therapy, 2014, 14, 1495-1513.	2.4	8
35	Thymidine phosphorylase: the unforeseen driver in colorectal cancer treatment?. Future Oncology, 2018, 14, 1223-1231.	2.4	8
36	Clinical and Molecular Features of Epidermal Growth Factor Receptor (EGFR) Mutation Positive Non-Small-Cell Lung Cancer (NSCLC) Patients Treated with Tyrosine Kinase Inhibitors (TKIs): Predictive and Prognostic Role of Co-Mutations. Cancers, 2021, 13, 2425.	3.7	7

Paolo Bironzo

#	Article	IF	CITATIONS
37	DNA Methylation Profiling Discriminates between Malignant Pleural Mesothelioma and Neoplastic or Reactive Histologic Mimics. Journal of Molecular Diagnostics, 2021, 23, 834-846.	2.8	7
38	Repositioning PARP inhibitors in the treatment of thoracic malignancies. Cancer Treatment Reviews, 2021, 99, 102256.	7.7	7
39	SKP2 drives the sensitivity to neddylation inhibitors and cisplatin in malignant pleural mesothelioma. Journal of Experimental and Clinical Cancer Research, 2022, 41, 75.	8.6	7
40	Neoadjuvant chemo-radiotherapy for locally advanced esophageal cancer: A monocentric study. Tumori, 2012, 98, 451-457.	1.1	6
41	Italian survey on the clinical management of non-small cell lung cancer patients during the COVID-19 pandemic: A lesson for the second wave. Critical Reviews in Oncology/Hematology, 2021, 157, 103189.	4.4	6
42	Dealing with NSCLC EGFR mutation testing and treatment: A comprehensive review with an Italian real-world perspective. Critical Reviews in Oncology/Hematology, 2021, 160, 103300.	4.4	6
43	Immune-checkpoint inhibition in stage III unresectable NSCLC: Challenges and opportunities in the post-PACIFIC era. Lung Cancer, 2021, 157, 85-91.	2.0	6
44	Immune checkpoint inhibitors a new player in the therapeutic game of mesothelioma: New reality with new challenges. Cancer Treatment Reviews, 2021, 99, 102250.	7.7	6
45	AISF position paper on HCV in immunocompromised patients. Digestive and Liver Disease, 2019, 51, 10-23.	0.9	5
46	SARS-CoV-2 Infection in Cancer Patients: A Picture of an Italian Onco-Covid Unit. Frontiers in Oncology, 2020, 10, 1722.	2.8	5
47	Five-year overall survival of pembrolizumab in advanced non-small cell lung cancer: another step from care to cure?. Annals of Translational Medicine, 2019, 7, S212-S212.	1.7	5
48	Nutritional support in lung cancer: Time to combine immunonutrition with immunotherapy?. Nutrition, 2022, 98, 111637.	2.4	5
49	Oligoprogressive Disease With SCLC Transformation in EGFR-Mutated NSCLC: How Biology Knowledge Can Change the Game Rules. Journal of Thoracic Oncology, 2020, 15, e170-e172.	1.1	4
50	Evaluation of the Preclinical Efficacy of Lurbinectedin in Malignant Pleural Mesothelioma. Cancers, 2021, 13, 2332.	3.7	4
51	Squamous cell histological transformation in a lung adenocarcinoma patient (hyper) progressing upon immunotherapy. Tumori, 2022, 108, NP15-NP19.	1.1	4
52	Diagnostics of BAP1-Tumor Predisposition Syndrome by a Multitesting Approach: A Ten-Year-Long Experience. Diagnostics, 2022, 12, 1710.	2.6	4
53	First-line immune-chemotherapy combination: the right strategy to fight squamous non-small cell lung cancer?. Translational Lung Cancer Research, 2019, 8, 546-549.	2.8	3
54	Descriptive Comparative Analysis of Patients With Cancer Referring to the Emergency Department of an Italian University Hospital Across the Severe Acute Respiratory Syndrome Coronavirus 2 Waves. JCO Oncology Practice, 2021, 17, OP.21.00098.	2.9	3

PAOLO BIRONZO

#	Article	IF	CITATIONS
55	Future perspectives from lung cancer pre-clinical models: new treatments are coming?. Translational Lung Cancer Research, 2020, 9, 2629-2644.	2.8	3
56	Pemetrexed, Vitamin B12, and Thoracic Tumors: The Times, They Are A-Changin'. Clinical Lung Cancer, 2018, 19, 461-463.	2.6	2
57	Is there any place for immune-checkpoint inhibitors in the treatment algorithm of fusion-driven non-small cell lung cancer?—a literature review. Translational Lung Cancer Research, 2020, 9, 2674-2685.	2.8	2
58	MET exon 14 mutation: another actionable genomic variation in patients with advanced NSCLC. Translational Cancer Research, 2016, 5, S101-S105.	1.0	1
59	Raising the bar for enthusiasm when looking at results of randomized phase II trials-the case of sunitinib in small-cell lung cancer. Translational Lung Cancer Research, 2016, 5, 89-91.	2.8	1
60	Micro-RNA-215 and -375 regulate thymidylate synthase protein expression in pleural mesothelioma and mediate epithelial to mesenchymal transition. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2022, , 1.	2.8	1
61	Squamous carcinoma of the lung: still a long and winding road to successful treatment. Lung Cancer Management, 2014, 3, 365-368.	1.5	Ο
62	NIBIT-MESO-1: limitations and clinical perspectives in MPM treatment testing an immune checkpoint blockade combination in a single-arm study. Journal of Thoracic Disease, 2018, 10, S3878-S3881.	1.4	0
63	Local for advanced, is this a paradox?. Translational Lung Cancer Research, 2021, 10, 3324-3328.	2.8	Ο
64	Winds From the ORIENT: New Data to Inform RATIONAL Choice?. Journal of Thoracic Oncology, 2021, 16, 1434-1436.	1.1	0
65	Next-generation sequencing in malignant pleural mesothelioma: A retrospective study Journal of Clinical Oncology, 2014, 32, 7530-7530.	1.6	0
66	How to Personalize Perioperative Chemotherapy in Early Non-small Cell Lung Cancer?. , 2015, , 49-66.		0
67	Biases in assessment and reporting of health-related quality of life (QoL): A systematic review of oncology randomized phase III trials published between 2012 and 2016 Journal of Clinical Oncology, 2018, 36, e18719-e18719.	1.6	О
68	Achievements in targeted therapies. , 0, , 215-233.		0
69	Phase III study with atezolizumab versus placebo in patients with malignant pleural mesothelioma after pleurectomy/decortication (AtezoMeso study) Journal of Clinical Oncology, 2022, 40,	1.6	О